ZA200903279B - Compounds for inhibiting mitotic progression - Google Patents

Compounds for inhibiting mitotic progression

Info

Publication number
ZA200903279B
ZA200903279B ZA200903279A ZA200903279A ZA200903279B ZA 200903279 B ZA200903279 B ZA 200903279B ZA 200903279 A ZA200903279 A ZA 200903279A ZA 200903279 A ZA200903279 A ZA 200903279A ZA 200903279 B ZA200903279 B ZA 200903279B
Authority
ZA
South Africa
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
progression
Prior art date
Application number
ZA200903279A
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200903279(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ZA200903279B publication Critical patent/ZA200903279B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200903279A 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression ZA200903279B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
ZA200903279B true ZA200903279B (en) 2010-07-28

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903279A ZA200903279B (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Country Status (35)

Country Link
US (6) US8026246B2 (fr)
EP (4) EP2497772B1 (fr)
JP (3) JP5102839B2 (fr)
KR (2) KR101110458B1 (fr)
CN (2) CN101547924B (fr)
AR (1) AR064246A1 (fr)
AT (1) ATE556076T1 (fr)
AU (1) AU2007322046B2 (fr)
BR (1) BRPI0718803B8 (fr)
CA (1) CA2669680C (fr)
CL (1) CL2007003244A1 (fr)
CR (3) CR10782A (fr)
CY (1) CY1112828T1 (fr)
DK (2) DK2086981T3 (fr)
EA (1) EA015779B1 (fr)
ES (3) ES2384123T3 (fr)
GE (1) GEP20125459B (fr)
HK (4) HK1134672A1 (fr)
HR (2) HRP20120490T1 (fr)
IL (1) IL198690A0 (fr)
MA (1) MA30988B1 (fr)
MX (3) MX343391B (fr)
MY (1) MY153243A (fr)
NO (1) NO343338B1 (fr)
NZ (3) NZ611898A (fr)
PH (1) PH12012502057A1 (fr)
PL (2) PL2086981T3 (fr)
PT (2) PT2086981E (fr)
RS (2) RS53788B1 (fr)
SG (2) SG176443A1 (fr)
SI (2) SI2086981T1 (fr)
TW (1) TWI401255B (fr)
UA (1) UA94129C2 (fr)
WO (1) WO2008063525A1 (fr)
ZA (1) ZA200903279B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TW201026703A (en) * 2008-12-05 2010-07-16 Millennium Pharm Inc Thiolactams and uses thereof
WO2010074724A1 (fr) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Inhibiteurs d'aurora kinases associés avec des anticorps anti-cd20
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105209042B (zh) * 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CN107205933A (zh) * 2014-12-23 2017-09-26 米伦纽姆医药公司 Raf抑制剂与aurora激酶抑制剂的组合
WO2017015316A1 (fr) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur de kinase aurora et d'agents chimiothérapeutiques
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
CA2997769A1 (fr) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Sulfonamides heterocycliques tricycliques contraints en tant qu'agents anti-cancereux
WO2017146253A1 (fr) 2016-02-26 2017-08-31 公益財団法人がん研究会 Procédé de criblage d'agent anticancéreux focalisé sur la fonction de hp1, et système d'évaluation
WO2017157825A1 (fr) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinaisons d'inhibiteurs de lsd1 pour leur utilisation dans le traitement des tumeurs solides
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (fr) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida
WO2021041532A1 (fr) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1
WO2023196959A1 (fr) 2022-04-07 2023-10-12 Eli Lilly And Company Procédé de fabrication d'un inhibiteur de kras g12c
WO2023196887A1 (fr) 2022-04-08 2023-10-12 Eli Lilly And Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (fr) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) * 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ID24101A (id) 1997-09-29 2000-07-06 Meiji Seika Kaisha Turunan-turunan triazolobenzazepine trisiklik, proses pembuatan yang sama, dan zat-zat antialergi
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (fr) 1999-05-12 2000-11-16 Nitromed, Inc. Activateurs nitroses et nitrosyles du canal potassique, compositions et utilisations
WO2001042199A1 (fr) 1999-12-06 2001-06-14 Ajinomoto Co.,Inc. Derive de l'acide amidinophenylpyruvique
PT1345922E (pt) * 2000-12-21 2006-09-29 Vertex Pharma Compostos de pirazole uteis como inibidores de proteina-quinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
AU2002328999B8 (en) 2001-08-09 2008-06-05 Actelion Pharmaceuticals Ltd. Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
CA2587427A1 (fr) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Inhibiteurs de kinase
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
CN103483343A (zh) 2014-01-01
HK1175777A1 (en) 2013-07-12
CA2669680C (fr) 2012-04-10
CN101547924B (zh) 2013-09-25
DK2086981T3 (da) 2012-08-06
ATE556076T1 (de) 2012-05-15
ES2528793T3 (es) 2015-02-12
CR10782A (es) 2009-06-24
NZ577042A (en) 2012-03-30
SG10201503350TA (en) 2015-06-29
CA2669680A1 (fr) 2008-05-29
US20210214361A1 (en) 2021-07-15
KR101342014B1 (ko) 2013-12-19
KR101110458B1 (ko) 2012-03-13
BRPI0718803B1 (pt) 2020-11-17
ES2537451T3 (es) 2015-06-08
MX348568B (es) 2017-06-20
HK1134672A1 (en) 2010-05-07
EP2497772A1 (fr) 2012-09-12
PH12012502057B1 (en) 2015-09-14
RS53788B1 (en) 2015-06-30
EP2497773B1 (fr) 2015-02-25
PL2497772T3 (pl) 2015-05-29
SG176443A1 (en) 2011-12-29
US20080167292A1 (en) 2008-07-10
EA015779B1 (ru) 2011-12-30
US9765076B2 (en) 2017-09-19
CR20140154A (es) 2014-07-23
US9988384B2 (en) 2018-06-05
AR064246A1 (es) 2009-03-25
NZ597252A (en) 2013-06-28
CY1112828T1 (el) 2016-02-10
BRPI0718803B8 (pt) 2021-05-25
MX343391B (es) 2016-11-04
US11958855B2 (en) 2024-04-16
PH12012502057A1 (en) 2015-09-14
CL2007003244A1 (es) 2008-04-04
CN103483343B (zh) 2016-06-01
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2944639B1 (fr) 2017-01-04
JP2010510215A (ja) 2010-04-02
US20150166545A1 (en) 2015-06-18
CN101547924A (zh) 2009-09-30
HRP20150047T1 (en) 2015-03-13
BRPI0718803A2 (pt) 2013-12-03
MA30988B1 (fr) 2009-12-01
US20110312942A1 (en) 2011-12-22
HK1217699A1 (zh) 2017-01-20
IL198690A0 (en) 2010-02-17
JP5452811B2 (ja) 2014-03-26
WO2008063525A1 (fr) 2008-05-29
KR20110113210A (ko) 2011-10-14
EP2944639A1 (fr) 2015-11-18
EP2086981B1 (fr) 2012-05-02
US8026246B2 (en) 2011-09-27
PL2086981T3 (pl) 2012-09-28
HK1175778A1 (en) 2013-07-12
UA94129C2 (ru) 2011-04-11
PT2497772E (pt) 2015-02-05
CR20140544A (es) 2015-01-12
TWI401255B (zh) 2013-07-11
GEP20125459B (en) 2012-03-26
US20110312943A1 (en) 2011-12-22
RS52313B (en) 2012-12-31
ES2384123T3 (es) 2012-06-29
EP2086981A1 (fr) 2009-08-12
SI2086981T1 (sl) 2012-12-31
MY153243A (en) 2015-01-29
EA200970486A1 (ru) 2009-10-30
EP2497772B1 (fr) 2014-10-29
JP5102839B2 (ja) 2012-12-19
US10836766B2 (en) 2020-11-17
HRP20120490T1 (hr) 2012-07-31
EP2497773A1 (fr) 2012-09-12
NO343338B1 (no) 2019-02-04
AU2007322046A1 (en) 2008-05-29
NO20091864L (no) 2009-06-15
DK2497772T3 (en) 2015-01-19
KR20090091173A (ko) 2009-08-26
JP2012006965A (ja) 2012-01-12
SI2497772T1 (sl) 2015-03-31
AU2007322046B2 (en) 2012-04-05
TW200829589A (en) 2008-07-16
JP2014055166A (ja) 2014-03-27
US20190031662A1 (en) 2019-01-31
NZ611898A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
HK1217699A1 (zh) 抑制有絲分裂的化合物
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (fr) Composes anti-arenaviridae
EP2082022A4 (fr) Composés
EP2004174A4 (fr) Composés de naphtalènedione
GB0602042D0 (en) Compounds
EP1973905A4 (fr) Composes
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (fr) Composé de bis-pyridine
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0600426D0 (en) Compounds
GB0602559D0 (en) Compounds
GB0603129D0 (en) Compounds
GB0600929D0 (en) Compounds
GB0605588D0 (en) Compounds
GB0605540D0 (en) Compounds
GB0605539D0 (en) Compounds
GB0602853D0 (en) Compounds
GB0602451D0 (en) Compounds
GB0602454D0 (en) Compounds
GB0602455D0 (en) Compounds
GB0601505D0 (en) Compounds